Fig. 8

The results of ChIP-seq validation. In the three different kinds of B Lymphocyte in Hodgkin’s Lymphoma and Burkitt’s Lymphoma (Raji, Namalwa and L428 cells) (PRJNA190710), compared to the control group, the binding regions of PAX5 in LTB showed more bonding strength (input samples) (a). Similarly, more bonding strength of PAX5 and LTB was also illustrated in the NALM6, DOHH2, OCI-LY-7, GM1287 and GM12892 cells comparing to the control group (PRJNA63447, PRJNA285847 and PRJNA475974) (b). Besides, in Pax5 ChIP-seq data of activated B cells and plasmablasts (mus musculus), upregulated binding peaks were also found in Ltb sequences (PRJNA625028) (c). What’s more, binding peaks of Ltb were higher in activated B cells and plasmablasts from IghPax5/+ mice than the control group